ALXO - ALX Oncology Holdings Inc

-

$undefined

N/A

(N/A)

ALX Oncology Holdings Inc NasdaqGS:ALXO ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Location: 323 Allerton Avenue, South San Francisco, CA, 94080, United States | Website: https://www.alxoncology.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-56.28M

Cash

97.83M

Avg Qtr Burn

-27.16M

Short % of Float

18.59%

Insider Ownership

2.45%

Institutional Own.

79.81%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Evorpacept (ALX148) + Keytruda Details
Head and neck cancer, Cancer

Big Mover™

Phase 2

Data readout

Evorpacept (ALX148) + Keytruda Details
Cancer, Platinum-resistant ovarian cancer

Phase 2

Data readout

Evorpacept + cetuximab + pembrolizumab Details
Cancer, Metastatic colorectal cancer

Phase 2

Update

Phase 2

Update

Phase 1/2

Data readout

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1

Data readout

Phase 1

Data readout

ALX2004 Details
EGFR-expressing solid tumors

Phase 1

Initiation

Evorpacept (ALX148) + Venetoclax Details
Cancer, Acute myeloid leukemia

Failed

Discontinued

Failed

Discontinued